Clinical trial NCT02107846: An Open-Label, Dose Escalation Study to Evaluate the Safety and the Pharmacokinetics of Oral PRX-112
Official title: A Phase 2a, Open-Label, Sequential Dose Escalation Study to Evaluate the Safety and the Pharmacokinetics of Oral PRX-112 (Plant Recombinant Human Glucocerebrosidase) in Enzyme Replacement Therapy-Naïve Subjects With Gaucher Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Gaucher Disease
Lead sponsor: Protalix
Sponsor class: INDUSTRY
First posted: 2014-04-08
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is an open-label, dose escalation study to evaluate the safety of oral PRX-112 and pharmacokinetics of GCD in subjects with Gaucher disease naive to enzyme replacement therapy. The dose levels of PRX-112 are 50 units, 100 units, 200 units and 400 units GCD. Subjects will receive once daily oral administrations of PRX-112 for 5 consecutive days at each dose level with a 2-day washout period between doses.


Eligibility criteria: Inclusion Criteria:

* Male or female age 18 or older
* Historical diagnosis of Gaucher disease by low leukocyte GCD activity level
* Haemoglobin ≥ 10 g/dL
* Body mass index (BMI) of 18 kg/m2-30 kg/m2 inclusive
* Subject is able to provide written informed consent
* Female subjects of child bearing potential must not be pregnant or lactating with a negative urine pregnancy test result at the screening visit.
* Female subjects of child-bearing potential and male subjects with female partners of childbearing potential must use two methods of contraception at all times during the study, one of which must be a barrier method. Acceptable methods of contraception are oral contraceptives, barrier methods (male condom, female condom, diaphragm, cervical cap, spermicide or intrauterine device), surgical sterility (documented doctor's report of vasectomy, hysterectomy and/or bilateral oophorectomy) and/or postmenopausal status (defined as at least 1 year without menses as demonstrated by medical history or subject report).
* Negative laboratory tests for HIV, HBsAg and HCV at the screening visit
* Naïve to any previous ERT or have received the last ERT treatment 12 months before signing IC

Exclusion Criteria:

* Presence of a gastrointestinal (GI) disease affecting motility or absorption
* Subjects with any history of allergic response to biological drugs or other allergies deemed clinically significant by the Investigator
* Reported history of alcohol or drug abuse
* Subject has donated blood in the 3 months prior to screening or subject has received plasma derivatives in the 6 months prior to screening
* Use of any investigational drug or participation in another clinical trial in the 3 months prior to screening (subject report)
* Subjects who have previously received ERT with positive anti-human plant recombinant GCD (prGCD) antibodies
* Clinical evidence of any active significant disease that could potentially compromise the ability of the Investigator to evaluate or interpret the effects of the study treatment on safety assessment, thus increasing the risk to the subject to unacceptable levels
* Presence of any medical, emotional, behavioural or psychological condition that, in the judgement of the Investigator, would interfere the compliance requirements of the study
* Subject has used any medication (excluding acetaminophen or dyprione) within 7 days of screening, including laxatives, teas and food additives known to be used for the treatment of constipation or diarrhea

Primary outcomes:
measure: Area under the curve
timeFrame: 24 hours
measure: Adverse Events
timeFrame: 7 Days
Secondary outcomes:
Other outcomes:
Locations:
city: Jerusalem
country: Israel
facility: Shaare Zedek Medical Center
Study officials:
References: